Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals
Embodiments of this invention provide methods for therapeutic use of cyclic G-2-Allyl Proline to treat cognitive disorders as well as manufacture of medicaments including tablets, capsules, injectable solutions that are useful for treatment of such conditions.
1. A method for relieving or alleviating a symptom of cognitive dysfunction caused by a disease, injury, or condition in a mammal in need thereof, comprising: administering a pharmaceutically effective amount of cyclic Glycyl-2-Allyl Proline (cG-2-AllylP) to said mammal thereby providing relief from the symptom, where said symptom is loss of spatial memory, loss of long-term memory, or loss of novelty recognition.
2. The method of claim 1 , where said disease is Alzheimer's disease.
3. The method of claim 1 , where said disease is Huntington's disease.
4. The method of claim 1 , where said disease is Lewy Body disease.
5. The method of claim 1 , where said disease is Dementia.
6. The method of claim 1 , where said disease is cerebral atrophy.
7. The method of claim 1 , where said disease is frontotemporal lobar degeneration.
8. The method of claim 1 , where said disease is Pick's disease.
9. The method of claim 1 , where said disease is multi-infarct dementia.
10. The method of claim 1 , where said disease is HIV infection.
11. The method of claim 1 , where said disease is Down's syndrome.
12. The method of claim 1 , where said injury is neurotoxic injury.
13. The method of claim 1 , where said injury is cerebral hypoxia/ischemia.
14. The method of claim 1 , where said injury is traumatic brain injury.
15. The method of claim 1 , where said injury is coronary artery bypass surgery.
16. The method of claim 1 , where said condition is normal aging.
17. The method of claim 1 , where said condition is age-related memory loss.
18. The method of claim 1 , where said condition is cholinergic hypofunction.
19. The method of claim 18 , where said cholinergic hypofunction is caused by scopolamine.
20. The method of claim 1 , wherein said cognitive dysfunction is caused by a decrease in glutamate receptors in the granular cell layer (CA1) of the hippocampus of said mammal.
21. The method of claim 1 , where said condition is vascular narrowing or blockage in the brain.
22. The method of claim 1 , said condition is decreased cerebral perfusion.
23. The method of claim 1 , where said condition is, neuroinflammation.
24. The method of claim 1 , where said condition is mild cognitive impairment.
25. The method of claim 1 , where said condition is loss of synaptic plasticity.
26. The method of claim 1 , wherein said cG-2-AllylP comprises an aqueous solution and one or more pharmaceutically acceptable excipients, additives, carriers or adjuvants.
27. The method of claim 1 , wherein said cG-2-AllylP further comprises one or more excipients, carriers, additives, adjuvants, or binders in a tablet or capsule.
28. The method of claim 1 , wherein said cyclic G-2-AllylP is administered via an oral, intraperitoneal, intravascular, peripheral circulation, subcutaneous, intraorbital, ophthalmic, intraspinal, intracisternal, topical, infusion, implant, aerosol, inhalation, scarification, intracapsular, intramuscular, intranasal, buccal, transdermal, pulmonary, rectal, or vaginal route.
29. The method of claim 1 , wherein said effective amount has a lower limit of about 0.001 milligrams per kilogram mass (mg/kg) of the animal and an upper limit of about 100 mg/kg.